公开(公告)号：US20230312565A1

公开(公告)日：2023-10-05

申请号：US18042069

申请日：2021-08-18

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Chunjian Liu ,  Alicia Regueiro-Ren

IPC分类号： C07D471/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  C07D519/00

摘要： The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

公开(公告)号：US20230303538A1

公开(公告)日：2023-09-28

申请号：US17927426

申请日：2021-05-27

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： CHUNJIAN LIU ,  Wei Wang ,  Bruce A. Ellsworth ,  James Aaron Balog ,  Alicia Regueiro-Ren

IPC分类号： C07D405/14

CPC分类号： C07D405/14

摘要： The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US20230295122A1

公开(公告)日：2023-09-21

申请号：US18041719

申请日：2021-08-18

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： David S. Yoon ,  Alicia Regueiro-Ren ,  Michael Mandler ,  Shoshana L. Posy ,  Chunjian Liu

IPC分类号： C07D401/14 ,  C07D451/04 ,  C07D471/04 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D235/18 ,  C07D519/00 ,  C07D405/12 ,  C07D401/10 ,  C07D487/10 ,  C07D487/04 ,  C07D403/10 ,  C07D401/12 ,  C07D451/02

CPC分类号： C07D401/14 ,  C07D451/04 ,  C07D471/04 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D235/18 ,  C07D519/00 ,  C07D405/12 ,  C07D401/10 ,  C07D487/10 ,  C07D487/04 ,  C07D403/10 ,  C07D401/12 ,  C07D451/02

摘要： The present invention relates to 1H-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

公开(公告)号：US20160075703A1

公开(公告)日：2016-03-17

申请号：US14878270

申请日：2015-10-08

申请人： Bristol-Myers Squibb Company

发明人： TAO WANG ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC分类号： C07D471/04 ,  C07D491/048

CPC分类号： C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

摘要： This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

公开(公告)号：US20150259342A1

公开(公告)日：2015-09-17

申请号：US14725298

申请日：2015-05-29

申请人： Bristol-Myers Squibb Company

发明人： Tao Wang ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC分类号： C07D471/04 ,  C07D491/048

CPC分类号： C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

摘要： This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: wherein Q is These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

摘要翻译： 本发明提供具有药物和生物影响性质的化合物，其药物组合物和使用方法。 特别地，本发明涉及具有式I的亚硝基二氧乙酰基哌嗪衍生物：其中Q是这些化合物具有独特的抗病毒活性，无论是单独使用还是与其它抗病毒剂，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。

公开(公告)号：US08889854B2

公开(公告)日：2014-11-18

申请号：US13799479

申请日：2013-03-13

申请人： Bristol-Myers Squibb Company

发明人： Ny Sin ,  Zheng Liu ,  Jacob Swidorski ,  Sing-Yuen Sit ,  Jie Chen ,  Yan Chen ,  Nicholas A. Meanwell ,  Alicia Regueiro-Ren

IPC分类号： C07J53/00 ,  C07D498/08 ,  C07D495/08 ,  C07D495/10 ,  C07D487/10 ,  C07J63/00 ,  C07D491/08 ,  C07D209/52 ,  C07D487/08

CPC分类号： C07D487/08 ,  C07D209/52 ,  C07D487/10 ,  C07D491/08 ,  C07D495/08 ,  C07D495/10 ,  C07D498/08 ,  C07J63/008

摘要： Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

摘要翻译： 阐述了具有药物和生物影响特性的化合物，其药物组合物和使用方法。 特别地，具有独特抗病毒活性的三萜类化合物的C-17二环胺作为HIV成熟抑制剂提供，如式I，II和III化合物所示：这些化合物可用于治疗HIV和AIDS。

公开(公告)号：US20140135342A1

公开(公告)日：2014-05-15

申请号：US14156718

申请日：2014-01-16

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Tao Wang ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC分类号： C07D471/04 ,  A61K45/06 ,  A61K31/496

CPC分类号： C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

摘要： This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

摘要翻译： 本发明提供具有药物和生物影响性质的化合物，其药物组合物和使用方法。 特别地，本发明涉及氮杂吲哚乙酰基哌嗪衍生物。 这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。

公开(公告)号：US20130072465A1

公开(公告)日：2013-03-21

申请号：US13623165

申请日：2012-09-20

申请人： Bristol-Myers Squibb Company

发明人： Zheng Liu ,  Nicholas A. Meanwell ,  Alicia Regueiro-Ren

IPC分类号： A61K31/58 ,  A61P31/18 ,  A61P31/12 ,  C07J53/00 ,  A61K31/565

CPC分类号： C07J63/008

摘要： Compounds of Formula I: that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

摘要翻译： 提供具有独特抗病毒活性的式I化合物作为HIV成熟抑制剂。 这些化合物可用于治疗艾滋病毒和艾滋病。

公开(公告)号：US20220144818A1

公开(公告)日：2022-05-12

申请号：US17601942

申请日：2020-04-08

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Chunjian Liu ,  Jianxin Feng ,  Pratik Devasthale ,  Natesan Murugesan ,  Bruce A. Ellsworth ,  Alicia Regueiro-Ren ,  Susheel Jethanand Nara ,  Prasada Rao Jalagam ,  Manoranjan Panda

IPC分类号： C07D417/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14

摘要： The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US11267811B2

公开(公告)日：2022-03-08

申请号：US16650403

申请日：2018-09-27

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Prasada Rao Jalagam ,  Satheesh Kesavan Nair ,  Manoranjan Panda ,  Ramakanth Sarabu ,  Jacob Swidorski ,  Brett R. Beno ,  Alicia Regueiro-Ren

IPC分类号： C07D417/14 ,  C07D405/14

摘要： The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.